| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701696 | Journal of Thoracic Oncology | 2017 | 14 Pages |
Abstract
This report provides the first detailed description of brain metastases in MET exon 14-positive NSCLC and provides preliminary support for the intracranial activity of cabozantinib. Prospective study is warranted and needed to refine the management of intracranial disease in MET exon 14-positive NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Samuel J. MD, Ali MD, Behrooz MD, Siraj M. MD, PhD, Sai-Hong Ignatius MD, PhD,